71 related articles for article (PubMed ID: 20105202)
1. 5-FU and mismatch repair deficient colorectal cancer: is it time to consider a change in practice?
Newton K; Hill J
Colorectal Dis; 2010 Jul; 12(7):706-7. PubMed ID: 20105202
[No Abstract] [Full Text] [Related]
2. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Piñol V; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Payá A; Alenda C;
Gut; 2006 Jun; 55(6):848-55. PubMed ID: 16299036
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of fluorouracil chemotherapy based on the genetic makeup of colorectal cancer.
Carethers JM
Gut; 2006 Dec; 55(12):1819. PubMed ID: 17124162
[No Abstract] [Full Text] [Related]
4. Prospective evaluation of fluorouracil chemotherapy based on the genetic makeup of colorectal cancer.
Carethers JM
Gut; 2006 Jun; 55(6):759-61. PubMed ID: 16698750
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapeutic agents for colorectal cancer with a defective mismatch repair system: the state of the art.
Valentini AM; Armentano R; Pirrelli M; Caruso ML
Cancer Treat Rev; 2006 Dec; 32(8):607-18. PubMed ID: 17055172
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.
Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Balaguer F; Sempere L; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Pons E; Payá A; Alenda C;
Eur J Cancer; 2009 Feb; 45(3):365-73. PubMed ID: 18722765
[TBL] [Abstract][Full Text] [Related]
7. Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin.
Cenni B; Kim HK; Bubley GJ; Aebi S; Fink D; Teicher BA; Howell SB; Christen RD
Br J Cancer; 1999 May; 80(5-6):699-704. PubMed ID: 10360646
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil.
de Angelis PM; Fjell B; Kravik KL; Haug T; Tunheim SH; Reichelt W; Beigi M; Clausen OP; Galteland E; Stokke T
Int J Oncol; 2004 May; 24(5):1279-88. PubMed ID: 15067352
[TBL] [Abstract][Full Text] [Related]
9. Microsatellite instability, mismatch repair deficiency, and colorectal cancer.
Gryfe R; Gallinger S
Surgery; 2001 Jul; 130(1):17-20. PubMed ID: 11436007
[No Abstract] [Full Text] [Related]
10. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.
Tang R; Wang JY; Fan CW; Tsao KC; Chen HH; Wu CM; Chen JS; Changchien CR; Hsieh LL
Cancer Lett; 2004 Jul; 210(1):101-9. PubMed ID: 15172127
[TBL] [Abstract][Full Text] [Related]
11. The relationship between 5-fluorouracil sensitivity and single nucleotide polymorphisms of the orotate phosphoribosyl transferase gene in colorectal cancer.
Kitajima M; Takita N; Hata M; Maeda T; Sakamoto K; Kamano T; Ochiai T
Oncol Rep; 2006 Jan; 15(1):161-5. PubMed ID: 16328050
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects.
Chen SP; Wu CC; Lin SZ; Kang JC; Su CC; Chen YL; Lin PC; Chiu SC; Pang CY; Harn HJ
Am J Clin Oncol; 2009 Apr; 32(2):122-6. PubMed ID: 19307944
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
14. The French experience with infusional 5-fluorouracil in advanced colorectal cancer.
de Gramont A; Louvet C; Krulik M
J Infus Chemother; 1996; 6(3):133-6. PubMed ID: 9229324
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience.
Wilson KS; Fitzgerald CA; Barnett JB; Gill S; Khoo KE
Cancer Invest; 2007 Dec; 25(8):711-4. PubMed ID: 18058467
[TBL] [Abstract][Full Text] [Related]
16. Chromosomal instability and p53 inactivation are required for genesis of glioblastoma but not for colorectal cancer in patients with germline mismatch repair gene mutation.
Leung SY; Yuen ST; Chan TL; Chan AS; Ho JW; Kwan K; Fan YW; Hung KN; Chung LP; Wyllie AH
Oncogene; 2000 Aug; 19(35):4079-83. PubMed ID: 10962567
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of microsatellite instability for benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
Jover R; Castells A; Llor X; Andreu M
Gut; 2006 Dec; 55(12):1819-20. PubMed ID: 17124161
[No Abstract] [Full Text] [Related]
18. [The mismatch-repair genes and colon cancer].
Moisio AL; Peltomäki P
Duodecim; 1996; 112(4):337-40. PubMed ID: 10590651
[No Abstract] [Full Text] [Related]
19. Predictive value of microsatellite instability for benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
Iacopetta B; Watanabe T
Gut; 2006 Nov; 55(11):1671-2. PubMed ID: 17047121
[No Abstract] [Full Text] [Related]
20. Chemotherapy of colorectal cancer: history and new themes.
Bertino JR
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-3-S18-7. PubMed ID: 9420015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
